Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of surgical oncology"
DOI: 10.1002/jso.26650
Abstract: BACKGROUND AND OBJECTIVES The impact of perioperative blood transfusion (PBT) on outcomes for pancreatic ductal adenocarcinoma (PDAC) patients given multimodality therapy (MMT) remains undefined. We sought to evaluate the association of PBT with survival after… read more here.
Keywords: given multimodality; multimodality therapy; patients given; therapy ... See more keywords
Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of surgical oncology"
DOI: 10.1002/jso.26859
Abstract: BACKGROUND AND METHODS: Racial and socioeconomic disparities in receipt of adjuvant chemotherapy affect patients with pancreatic cancer. However, differences in receipt of neoadjuvant chemotherapy among patients undergoing resection are not well-understood. A retrospective cross-sectional cohort of… read more here.
Keywords: chemotherapy; multimodality therapy; pancreatic cancer;
National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastrointestinal Surgery"
DOI: 10.1007/s11605-019-04361-3
Abstract: Studies have demonstrated that multimodality therapy and surgery at high volume centers are associated with a longer survival. However, it is unknown if these data have translated into national changes in care delivery. Patients with… read more here.
Keywords: high volume; 2004 2010; multimodality therapy; volume centers ... See more keywords
Multimodality therapy for thymoma patients with pleural dissemination
Sign Up to like & getrecommendations! Published in 2019 at "General Thoracic and Cardiovascular Surgery"
DOI: 10.1007/s11748-018-01054-7
Abstract: BackgroundAlthough multidisciplinary treatment is recommended for patients with advanced stage and recurrent thymoma, a detailed treatment strategy remains controversial. We have performed a multimodality therapy of induction chemotherapy (CAMP therapy: cisplatin, doxorubicin, and methylprednisolone) combined… read more here.
Keywords: multimodality therapy; thymoma patients; therapy; pleural dissemination ... See more keywords
Disparities in utilization of treatment for clinical stage I‐II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity
Sign Up to like & getrecommendations! Published in 2019 at "Surgery"
DOI: 10.1016/j.surg.2018.10.035
Abstract: Background: Utilization of multimodality therapy for clinical stage I‐II pancreatic ductal adenocarcinoma is associated with meaningful prolongation of survival. Although the qualitative existence of disparities in treatment utilization by socioeconomic status and race/ethnicity is well… read more here.
Keywords: status; multimodality therapy; race ethnicity; socioeconomic status ... See more keywords
Personalized multimodality therapy (ICT) with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT), in advanced/refractory cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15150
Abstract: e14254Background: Therapy for advanced refractory malignancies remains a major challenge. As the combination of ICI and CT has been shown in some cancers to be superior to CT alone, and as ICI, CT,... read more here.
Keywords: therapy; multimodality therapy; therapy ict; ict immune ... See more keywords